Oct, 03, 2022

Soleo Health Adds AMVUTTRA™ (vutrisiran) to Its Specialty Pharmacy Portfolio

Newly FDA-approved AMVUTTRA™ for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

FRISCO, Texas, October 3, 2022 – Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it has added AMVUTTRA™ (vutrisiran) to its specialty pharmacy portfolio to treat adults with the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

Soleo Health offers newly FDA-approved AMVUTTRA injections to patients in their homes (after an evaluation and recommendation by the treating physician) or at one of its ambulatory infusion centers (AICs) nationwide. Soleo Health employs specially trained interdisciplinary teams comprised of highly experienced pharmacists, registered nurses, reimbursement specialists and patient care ambassadors – each of whom is trained on the clinical profile and administration for AMVUTTRA.

“This marks the fourth therapy Soleo Health now offers from Alnylam Pharmaceuticals’ rare disease product portfolio further strengthening our ability to care for more patients living with rare disease who benefit from innovative new therapies like AMVUTTRA,” said Drew Walk, Soleo Health chief executive officer.

About Soleo Health

Frisco, Texas-based Soleo Health is an innovative national provider of complex specialty pharmacy services administered in the home or at alternate sites of care. Soleo Health’s interdisciplinary team comprises highly experienced physician specialists, nurse practitioners, clinical pharmacists, registered nurses, reimbursement specialists and patient care ambassadors collaborating with its referring partners.

The Company optimizes patient access solutions and delivers comprehensive services, leading to quantifiable clinical and economic value, resulting in positive patient experiences. Soleo Health has 21 pharmacy locations with national nursing coverage and pharmacy licensure in 50 states and is accredited by URAC, ACHC with Distinction in Rare Disease and Orphan Drugs and The Joint Commission. Additionally, the Company operates more than 40 infusion centers throughout the U.S.

Visit www.soleohealth.com or connect with Soleo Health on LinkedIn, Facebook and Twitter for more information.